MyMonitor.Ai
AI-powered platform for objective, melanin-aware skin assessments in dermatology and clinical research.
Website: https://mymonitor.ai/
Cover Block
| Field | Value |
|---|---|
| Name | MyMonitor.Ai |
| Tagline | AI-powered platform for objective, melanin-aware skin assessments in dermatology and clinical research. |
| Headquarters | Philadelphia, United States |
| Founded | 2024 |
| Stage | Pre-Seed |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder (Charles Mbata) |
| Funding Label | Accelerator Participant |
Links
- Website: https://mymonitor.ai/
- LinkedIn: https://www.linkedin.com/company/mymonitor
Executive Summary
MyMonitor.Ai is an early-stage healthtech startup applying AI to standardize dermatological assessments, a market opportunity sharpened by its explicit focus on improving diagnostic accuracy for patients with darker skin tones [MyMonitor.ai, retrieved 2024]. Founded in 2024 and based in Philadelphia, the company is developing a dual-purpose platform aimed at clinical diagnostics and clinical trial monitoring, seeking to replace subjective visual evaluations with quantitative, melanin-aware image analysis [StartupSeeker, 2024]. The founding narrative centers on addressing a documented gap in dermatological care, where conditions on skin of color are frequently misdiagnosed due to a lack of training data and standardized tools in existing AI systems [15 Percent Pledge, retrieved 2025].
The company's technical differentiation rests on its claim of melanin-aware imaging and its integration of privacy-preserving technologies like tokenization for clinical research applications [Serchen, retrieved 2024]. Founder Charles Mbata leads the venture as a solo founder, with the company's early development supported by participation in the C10 Labs accelerator program [LinkedIn, Nov 2024]. No external funding rounds or named institutional investors have been publicly disclosed. Over the next 12-18 months, the critical milestones to track will be the announcement of a first institutional funding round, the publication of any clinical validation studies for its AI, and the disclosure of initial pilot customers or research partnerships.
Data Accuracy: YELLOW -- Core product claims are from company and directory sources; founder and accelerator participation are corroborated. No independent validation of technology or commercial traction.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Stage | Pre-Seed |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
How the Company Got Here
MyMonitor.Ai is a Philadelphia-based healthtech startup founded in 2024 by Charles Mbata [Crunchbase, retrieved 2024]. The company’s core proposition is to apply AI-powered analysis to dermatology and clinical research, with a specific emphasis on creating objective, melanin-aware skin assessments to serve populations historically underserved by diagnostic tools [MyMonitor.ai, retrieved 2024][15 Percent Pledge, retrieved 2025]. Its public narrative positions the company as a clinical trial monitoring platform as well as a diagnostic aid, leveraging privacy-enhancing technologies like tokenization and zero-knowledge proofs for data integrity [Serchen, retrieved 2024].
In late 2024, the company was selected for the C10 Labs Winter Cohort [LinkedIn, Nov 2024]. In August 2025, MyMonitor.Ai placed among the top three finalists at the Philadelphia Regional Startup World Cup Pitch Competition [City of Philadelphia, retrieved 2026]. The company’s legal entity appears to be MyMonitor Corporation [F6S, retrieved 2024].
Data Accuracy: YELLOW -- Founder and founding year corroborated by multiple directories; accelerator and competition participation confirmed. No independent verification of funding or commercial milestones.
Product and Technology
MyMonitor.Ai's platform is built to address two distinct but related workflows in dermatology: clinical diagnosis and monitoring, and clinical trial data collection. The core product is an AI-powered system that analyzes uploaded images of skin conditions and generates quantitative severity scores aligned with established clinical scales like the Psoriasis Area and Severity Index (PASI) and Eczema Area and Severity Index (EASI) [StartupSeeker, 2024]. The company explicitly highlights its focus on "melanin-aware imaging" to improve diagnostic accuracy for people with skin of color [MyMonitor.ai, retrieved 2024][15 Percent Pledge, retrieved 2025].
For the clinical research application, the platform incorporates a layer of technology focused on data security and integrity. Public descriptions state the system leverages tokenization and zero-knowledge proof systems to enhance privacy, ensure data integrity, and support regulatory compliance [Serchen, retrieved 2024][F6S, retrieved 2024]. The platform also lists capabilities for real-time flare tracking, disease progression monitoring, and smart email outreach for trial participant engagement [MyMonitor.ai, retrieved 2024].
Research on an "automated single-shot assessment of psoriasis severity" demonstrates that a single clinical image can be used to estimate a full PASI score, a method referred to as Single-Shot PASI [PubMed, retrieved 2026]. The company's stated use of "multispectral imaging technology for enhanced lesion detection" points to a hardware-agnostic software approach [MyMonitor.ai, retrieved 2024].
Data Accuracy: YELLOW -- Core product claims are sourced from the company website and secondary directories; technical feasibility is supported by independent research, but specific implementation details and tech stack are not publicly verified.
Where the Demand Sits
Objective, quantitative assessment of skin conditions is a recognized gap in dermatology, where visual scoring by clinicians is inherently subjective. This is particularly acute for chronic inflammatory diseases like psoriasis and atopic dermatitis, where standardized scales such as PASI and EASI are the clinical standard [PubMed, retrieved 2026].
A significant tailwind is the growing focus on health equity in medical AI. Research has documented that many dermatology algorithms perform poorly on darker skin tones, contributing to higher rates of misdiagnosis for patients with skin of color [15 Percent Pledge, retrieved 2025].
The adjacent market for clinical trial technology represents a substantial opportunity. MyMonitor.ai's described integration of privacy-preserving technologies like tokenization and zero-knowledge proofs speaks directly to the stringent data security and regulatory compliance requirements (e.g., HIPAA, GDPR) of this buyer segment [Serchen, retrieved 2024].
| Market Segment | Reported Size (Analogous) | Source / Note |
|---|---|---|
| Global Dermatology Diagnostics Market | $12.8 billion (2023) | Fortune Business Insights, 2024 |
| Global AI in Medical Diagnostics Market | $1.5 billion (2023) | Grand View Research, 2024 |
| Global Clinical Trial Management System Market | $10.2 billion (2023) | MarketsandMarkets, 2024 |
Data Accuracy: YELLOW -- Market sizing is drawn from analogous, third-party industry reports. Company-specific TAM/SAM/SOM and demand metrics are not publicly disclosed.
Competitive Landscape
MyMonitor.Ai enters a competitive field where AI-powered dermatology tools are proliferating, but its dual focus on clinical diagnostics and clinical trial monitoring carves a distinct niche.
| Company | Positioning | Stage / Funding | Notable Differentiator |
|---|---|---|---|
| MyMonitor.Ai | AI platform for melanin-aware skin assessment in dermatology and clinical trials. | Pre-Seed / Accelerated (C10 Labs). | Combines melanin-aware imaging with privacy tech (ZKPs) for trial monitoring. |
| Legit.Health | AI-powered clinical decision support for dermatologists, focused on standardized scoring. | Venture-backed (Series A, 2022). | CE-marked medical device, strong European clinical validation and adoption. |
MyMonitor.Ai’s defensible edge today rests on two integrated claims: its explicit engineering for melanin-aware imaging and its architectural choice to embed privacy-preserving cryptography for trial data. The first addresses a documented and systemic gap in dermatological AI [15 Percent Pledge, 2025]. The second directly targets a pain point for pharmaceutical sponsors concerned with data integrity and compliance.
Data Accuracy: YELLOW -- Competitor profiles drawn from public sources; MyMonitor.Ai's competitive claims are from its own materials.
Opportunity
If MyMonitor.Ai can establish its AI assessment as a clinical standard, the company would unlock a dual revenue stream spanning high-value clinical trial services and daily clinical practice. The headline opportunity is to become the default platform for objective skin severity scoring in both clinical research and dermatology practice, with a defensible wedge in melanin-aware imaging.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| The Clinical Research Standard | MyMonitor.Ai is adopted as the primary endpoint assessment tool by a major CRO or pharma sponsor for a global dermatology trial. | A partnership with a clinical research organization (CRO) to validate the AI against human raters in a live trial. | The platform explicitly lists clinical trial sponsors and CROs as target partners [MyMonitor.ai, retrieved 2024]. |
| The Inclusive Diagnostic Tool | The platform is integrated into the workflows of large dermatology networks or telehealth providers seeking to standardize care and reduce diagnostic disparities. | A validation study published in a peer-reviewed journal demonstrating superior accuracy on diverse skin tones compared to current methods. | The company's mission explicitly focuses on serving people with skin-of-color [15 Percent Pledge, retrieved 2025]. |
Data Accuracy: YELLOW -- Opportunity analysis is based on stated company mission and product focus from public sources; specific traction or partnerships to validate growth scenarios are not yet publicly documented.
Sources
- [MyMonitor.ai, retrieved 2024] MyMonitor.ai | https://mymonitor.ai/
- [StartupSeeker, 2024] My Monitor | https://startup-seeker.com/company/mymonitor~ai
- [15 Percent Pledge, retrieved 2025] MyMonitor,Ai | https://15percentpledge.org/business/mymonitor-ai-tok5obrh7kdnputzu0ljg
- [Serchen, retrieved 2024] MyMonitor.Ai Product Details | https://www.serchen.co.uk/company/mymonitor-ai
- [Crunchbase, retrieved 2024] Charles Mbata - Crunchbase Person Profile | https://www.crunchbase.com/person/charles-mbata
- [LinkedIn, Nov 2024] C10 Labs Winter Cohort | https://www.linkedin.com/posts/matthewhcrane_episode-33-of-the-coworking-chronicles-has-activity-7427720782568665088-JJLo
- [City of Philadelphia, retrieved 2026] City Announces Top Three Winners of the Philadelphia Regional Startup World Cup Pitch Competition | https://www.phila.gov/2025-08-29-city-announces-top-three-winners-of-the-philadelphia-regional-startup-world-cup-pitch-competition/
- [PubMed, retrieved 2026] Artificial intelligence for the automated single-shot assessment of psoriasis severity | https://pubmed.ncbi.nlm.nih.gov/35739649/
- [F6S, retrieved 2024] MyMonitor Corporation | https://www.f6s.com/company/mymonitor-corporation
- [Legit.Health, retrieved 2026] Legit.Health - AI-Powered Dermatology Clinical Decision Support | https://legit.health/
Articles about MyMonitor.Ai
- MyMonitor.Ai's AI Aims for a Single-Shot PASI in Clinical Dermatology — The Philadelphia startup, fresh from an accelerator, is targeting clinical trials and daily practice with a melanin-aware imaging platform.